Definitions and Core Concepts

What CAD is—and what it is not

What is cold agglutinin disease?

Primary CAD is a clonal cold-antibody autoimmune hemolytic anemia in which a pathogenic, usually monoclonal IgM autoantibody binds red blood cells at lower temperatures and activates the classical complement pathway, leading predominantly to C3-mediated extravascular hemolysis.¹

Conceptual anchor:
The antibody initiates the process; complement largely determines the hemolytic phenotype.

Key defining elements

• presence of a monoclonal IgM autoantibody, usually κ-restricted²
• classical complement activation as the dominant effector mechanism³
• C3 deposition on red blood cells⁴
• predominantly hepatic extravascular clearance of complement-opsonized red blood cells⁵
• a chronic or relapsing disease course in most primary cases⁶

CAD is not simply “autoimmune hemolytic anemia triggered by cold.” It is a mechanistically distinct entity with its own biology, kinetics, and therapeutic vulnerabilities.⁷

What is a cold agglutinin?

A cold agglutinin is an antibody that binds red blood cell antigens more avidly at temperatures below core body temperature.⁸

Cold agglutinins vary widely in clinical significance. Some are incidental laboratory findings, while others are pathogenic because they bind red cells at physiologically relevant temperatures and activate complement.

In clinically significant cold-antibody hemolysis, the antibody is usually IgM, binds red cells in cooler peripheral circulation, may dissociate on rewarming, and can leave behind complement fragments that continue to mark the red cell for destruction.

Cold agglutinins versus cold agglutinin disorders

Cold agglutinins are commonly detectable in human sera, but most are low-titer, polyclonal, and clinically insignificant.⁹ The presence of a cold agglutinin does not equal cold agglutinin disease, and it does not necessarily imply clinically significant hemolysis.¹⁰

Important distinctions:

Incidental or transient cold agglutinins¹¹

• often polyclonal
• commonly post-infectious
• usually self-limited
• may cause mild or no hemolysis
• do not necessarily define a clinical syndrome

Secondary cold agglutinin syndrome

• cold agglutinin-mediated hemolysis occurring secondary to another condition
• may follow infection or occur with autoimmune disease or overt lymphoid malignancy
• may be transient or persistent depending on the underlying cause
• management focuses on the associated condition and supportive care, with CAD-directed therapy considered only when clinically appropriate

Primary cold agglutinin disease¹²

• typically monoclonal
• persistent
• complement-driven hemolysis
• usually associated with a clonal bone marrow disorder

Why clonality matters:¹³
Clonality implies a persistent antibody source. This is why primary CAD is usually chronic, while many incidental or infection-associated cold agglutinins are self-limited.

Failure to separate incidental or transient cold agglutinins, secondary cold agglutinin syndromes, and primary clonal CAD has historically led to diagnostic confusion and inappropriate therapy.

Table. Distinguishing cold agglutinins, secondary cold agglutinin syndrome, and primary CAD

Category	Antibody pattern	Typical context	Hemolysis	Expected trajectory	Clinical meaning
Incidental or transient cold agglutinins	often polyclonal, low titer	healthy individuals or after infection	none or mild	usually self-limited	a laboratory finding, not necessarily disease
Secondary cold agglutinin syndrome	often polyclonal or context-dependent	infection, autoimmune disease, overt lymphoid malignancy	variable, sometimes clinically significant	depends on the underlying condition	cold-antibody hemolysis occurring in another disease context
Primary CAD	usually monoclonal IgM, often κ-restricted	clonal marrow B-cell process	chronic complement-mediated hemolysis	persistent or relapsing	a distinct clinicopathologic entity
Mixed AIHA phenotype	IgG and C3 often both present on DAT	overlapping warm and cold mechanisms	variable	depends on dominant mechanism(s)	boundary condition requiring caution with classic CAD assumptions

Primary CAD versus secondary cold agglutinin syndrome

Primary CAD¹⁴

• chronic clonal disorder
• IgM produced by an indolent B-cell clone
• complement-mediated hemolysis intrinsic to the disease
• no overt associated condition driving the cold antibody process

Secondary cold agglutinin syndromes

Occurs in association with:¹⁵

• acute infections
• autoimmune diseases
• overt lymphoid malignancies

In secondary cold agglutinin syndrome, the cold antibody process is part of another disease context. In primary CAD, the cold antibody is produced by the clonal marrow process that defines the disease.

In secondary syndromes, treatment primarily targets the underlying condition. In primary CAD, therapy is directed toward complement activation, the clonal source, or both.

This distinction materially affects prognosis, evaluation for associated disease, monitoring strategy, and treatment selection.¹⁶

Thermal amplitude

Thermal amplitude is the highest temperature at which a cold agglutinin binds red blood cells.¹⁷

Why it matters¹⁸

• higher thermal amplitude → greater physiologic relevance
• is often more informative than titer alone in judging clinical relevance
• explains severe disease despite modest antibody levels

Antibodies capable of binding at near-core temperatures interact with erythrocytes in central circulation, not just acral regions, which explains disproportionate disease severity. An antibody that binds at 30 °C may be clinically dangerous, while one that binds only at 4 °C may be biologically irrelevant.

Complement as the central effector

In CAD:¹⁹

• the antibody initiates the process
• complement determines the phenotype

Key principles²⁰

• hemolysis is predominantly driven by classical pathway activation
• C3 deposition is dominant
• most destruction is extravascular
• terminal complement lysis is usually limited

This creates an important temporal uncoupling: the IgM antibody may detach as red cells return to warmer central circulation, but complement fragments can remain on the red-cell surface and continue to mark the cell for destruction.

Limited terminal pathway activation helps explain why CAD typically presents with chronic anemia rather than fulminant intravascular hemolysis. Host complement regulators on the red-cell surface restrict progression to full membrane-attack–complex formation.

This mechanism also explains therapeutic logic: proximal complement blockade can suppress hemolysis without eliminating the pathogenic clone.²¹

Clonality and bone marrow involvement

Most patients with primary CAD have:²²

• a detectable monoclonal IgM
• an underlying indolent B-cell lymphoproliferative disorder
• disease largely confined to bone marrow

Primary CAD is therefore best understood as a clonal marrow B-cell disorder with immune-mediated hemolytic manifestations, rather than a purely reactive autoimmune condition.²³

The precise classification of the underlying clone has evolved historically, underscoring that disease definitions reflect current biologic understanding rather than fixed categories.

Common clinical misconceptions

CAD is not:²⁴

• primarily IgG mediated
• predominantly splenic in clearance
• reliably steroid responsive
• defined by antibody titer alone
• a uniform or predictable disease

Steroid responsiveness is the exception, not the rule.

Misunderstanding what CAD is not has historically driven ineffective therapy.

Core conceptual summary

Cold agglutinin disease rests on three biologic pillars:

• clonality determines persistence
• complement determines phenotype
• thermal amplitude determines pathogenicity

CAD is therefore defined as much by complement biology as by anemia itself.

Its mechanism is defined.
Its expression is variable.
Its classification is useful but not absolute.

Effective care depends on knowing which features are definitional, which are variable, and which only appear important.